Home › Diffuse Large B-Cell Lymphoma › Indiana
Diffuse Large B-Cell Lymphoma clinical trials in Indiana
9 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in Indiana.
Cities in Indiana
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Northwest Cancer Center - Crown Point, Crown Point
- Northwest Oncology LLC, Dyer
- Saint Mary Medical Center, Hobart
- and 4 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06649812A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Fort Wayne Medical Oncology and Hematology ( Site 0149), Fort Wayne
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06717347A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- St Vincent Ascension at Peyton Manning Childrens Hospital, Indianapolis
- Investigative Clinical Research of Indiana, Noblesville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06091865Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
- IU Simon Comprehensive Cancer Center, Indianapolis
- Indiana Blood and Marrow Transplantation, Indianapolis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT06500273Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Indiana Blood and Marrow Transplantation, Indianapolis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 10, 2026 · NCT05852717Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Northwest Cancer Center - Main Campus, Crown Point
- Northwest Oncology LLC, Dyer
- Northwest Cancer Center - Hobart, Hobart
- and 5 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 20, 2025 · NCT05890352DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 7, 2023 · NCT04920617Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Goshen Center for Cancer Care, Goshen
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2022 · NCT04502394From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.